MedTrace Logo

Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS

NCT04801563 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-03-17

No results posted yet for this study

Summary

An "intention-to-treat" study to evaluate the impact of allogeneic HSCT with Total Marrow and Lymphoid irradiation (TMLI), followed by Treg/Tcon adoptive immunotherapy, on overall survival in patients affected by Myelodysplastic Syndrome (MDS), according to IPSS-R.

Conditions

  • MDS and Allogeneic Stem Cell Transplantation

Interventions

OTHER

MDS and AlloHSCT

Allogeneic stem cell transplantation, based on TMLI and followed by infusion of donor regulatory T cells and conventional T cells and purified donor CD34+ hematopoietic stem cells

Sponsors & Collaborators

  • University Of Perugia

    lead OTHER

Principal Investigators

  • Andrea Velardi, MD · University Of Perugia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-20
Primary Completion
2025-09-19
Completion
2025-09-19

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04801563 on ClinicalTrials.gov